For example, the PTKi sorafenib has been shown to abrogate the transcriptional downregulation of interferon regulatory factor 7 (IRF7), which resulted in an augmented CD8+CD107a+IFN-γ+ T cell response in mouse models of FLT-ITD+ AML[55]. This evidence concerns the gene LAMP1 and acute myeloid leukemia.